- Home
- TSHA vs LOVE Comparison
TSHA vs LOVE Comparison
Compare TSHA & LOVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- LOVE
- Stock Information
- Founded
- TSHA 2019
- LOVE 1998
- Country
- TSHA United States
- LOVE United States
- Employees
- TSHA N/A
- LOVE N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- LOVE Other Specialty Stores
- Sector
- TSHA Health Care
- LOVE Consumer Discretionary
- Exchange
- TSHA Nasdaq
- LOVE Nasdaq
- Market Cap
- TSHA 356.7M
- LOVE N/A
- IPO Year
- TSHA 2020
- LOVE 2018
- Fundamental
- Price
- TSHA $1.26
- LOVE $17.61
- Analyst Decision
- TSHA Strong Buy
- LOVE Strong Buy
- Analyst Count
- TSHA 8
- LOVE 5
- Target Price
- TSHA $6.63
- LOVE $38.40
- AVG Volume (30 Days)
- TSHA 2.4M
- LOVE 509.2K
- Earning Date
- TSHA 05-13-2025
- LOVE 04-10-2025
- Dividend Yield
- TSHA N/A
- LOVE N/A
- EPS Growth
- TSHA N/A
- LOVE N/A
- EPS
- TSHA N/A
- LOVE 0.43
- Revenue
- TSHA $8,333,000.00
- LOVE $689,645,000.00
- Revenue This Year
- TSHA N/A
- LOVE N/A
- Revenue Next Year
- TSHA N/A
- LOVE $5.98
- P/E Ratio
- TSHA N/A
- LOVE $41.10
- Revenue Growth
- TSHA N/A
- LOVE 0.20
- 52 Week Low
- TSHA $1.17
- LOVE $15.22
- 52 Week High
- TSHA $4.32
- LOVE $39.49
- Technical
- Relative Strength Index (RSI)
- TSHA 32.22
- LOVE 44.15
- Support Level
- TSHA $1.17
- LOVE $16.95
- Resistance Level
- TSHA $1.87
- LOVE $18.88
- Average True Range (ATR)
- TSHA 0.17
- LOVE 0.82
- MACD
- TSHA -0.04
- LOVE 0.45
- Stochastic Oscillator
- TSHA 12.18
- LOVE 80.87
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.